Psychiatry researchHumansSchizophreniaPaliperidone PalmitateMaleFemale
12-Month mirror study on the effectiveness and safety of six-month paliperidone palmitate in patients with schizophrenia: A Multicenter Andalusian Cohort (PAPSEM study).
Jesús García-Jiménez, Óscar Lafuente-Casanova, Rosario Salas, Carlota Rodríguez, Miguel Graciani-Pérez, Pablo Roque Leonardo-Caserta, Manuel López-Arroyo, Asunta Torres-Laborde, Luis Gutiérrez-Rojas
Published: 202610.1016/j.psychres.2025.116903
Abstract
BACKGROUND: Paliperidone palmitate 6-month formulation (PP6M) offers a promising alternative for maintaining treatment adherence and reducing relapse risk in patients with schizophrenia. However, real-world data on its long-term effectiveness and saf…
Preview only. Read the full abstract at the source